Back to Results
First PageMeta Content
Amines / Serotonin-norepinephrine reuptake inhibitors / Duloxetine / Thiophenes / Selective serotonin reuptake inhibitors / Antidepressant / Paroxetine / Generalized anxiety disorder / Norepinephrine / Chemistry / Organic chemistry / Eli Lilly and Company


DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857
Add to Reading List

Open Document

File Size: 50,63 KB

Share Result on Facebook

City

Beltsville / Indianapolis / MSPAS / MACMIS / /

Company

Eli Lilly and Company / NDA 21 / Lilly Technology Center Indianapolis / Lilly Research Laboratories / /

Event

FDA Phase / Music Album Release / /

Facility

Company Lilly Technology Center / /

/

IndustryTerm

treatment of generalized anxiety disorder / acidic media / treatment of major depressive disorder / /

MedicalCondition

Concomitant Illness / abdominal pain / major depressive disorder / myoclonus / chronic liver disease / coma / peripheral neuropathy / mydriasis / uncontrolled narrow-angle glaucoma / pain / certain other psychiatric disorders / psychiatric disorders / delirium / hepatitis / liver injury / end-stage renal disease / Depression / generalized anxiety disorder / hepatic insufficiency / /

MedicalTreatment

antidepressant therapy / /

MusicAlbum

Capsules / /

Organization

Food and Drug Administration / U.S. Food and Drug Administration / Division of Drug Marketing / Advertising / and Communications / Regional Congress / Center for Drug Evaluation and Research / DEPARTMENT OF HEALTH / /

Person

Slide Kit / Michelle Safarik / Michele Sharp / /

Position

PRECAUTIONS General / Cymbalta Endo Speaker / PA-C Regulatory Review Officer / General / Manager / U.S. Regulatory Affairs / /

Product

CYMBALTA / CYM20050314F / MACMIS / CYMBALTA® (duloxetine hydrochloride) / /

ProvinceOrState

Maryland / Indiana / /

SocialTag